<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399773</url>
  </required_header>
  <id_info>
    <org_study_id>9910</org_study_id>
    <secondary_id>NCI-2017-02205</secondary_id>
    <secondary_id>9910</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>P50HL110787</secondary_id>
    <nct_id>NCT03399773</nct_id>
  </id_info>
  <brief_title>Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>Infusion of Off the Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (NLA101) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nohla Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Nohla Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of ex vivo expanded cord blood progenitor cells
      (NLA101) on outcomes from single cord blood transplant for hematologic malignancies. Before
      the transplant, patients will receive chemotherapy (fludarabine, cyclophosphamide and in some
      cases thiotepa) and radiation therapy. Giving chemotherapy and total-body irradiation before
      a donor umbilical cord blood transplant helps stop the growth of cells in the bone marrow,
      including normal blood-forming cells (stem cells) and cancer cells. It may also stop the
      patient's immune system from rejecting the donor's stem cells. When the healthy stem cells
      from a donor are infused into the patient they may help the patient's bone marrow make stem
      cells, red blood cells, white blood cells, and platelets. The donated stem cells may also
      replace the patient's immune cells and help destroy any remaining cancer cells. NLA101 is
      intended to support neutrophil engraftment and reduce GVHD following transplant.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Development halted in HSCT.
  </why_stopped>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of graft failure</measure>
    <time_frame>Up to 45 days post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of CTCAE Grade &gt;=3 Adverse Events within the first 24 hours after infusion</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to 45 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe acute graft-versus-host disease (GVHD)</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease (GVHD)</measure>
    <time_frame>Up to 2-years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality</measure>
    <time_frame>Up to 1-year post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive either regimen A (High Dose TBI) or regimen B (Intermediate Dose).
REGIMEN A: Patients (18 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.
REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 and -4, and TBI on days -2 and -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>NLA101</other_name>
    <other_name>Dilanubicel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Criteria:

        Inclusion Criteria:

          -  Patient must have hematologic malignancy that meets institutional eligibility
             requirements for cord blood transplant

          -  Malignancies included are:

               -  Acute leukemia, including acute myeloid leukemia (AML), biphenotypic acute
                  leukemia or mixed-lineage leukemia, acute lymphoblastic leukemia (ALL)

               -  Myelodysplasia (MDS)

               -  Chronic Myeloid Leukemia (CML)

          -  High dose TBI regimen: 18 to =&lt; 45 years

          -  Intermediate intensity regimen: 18 to =&lt; 65 years

          -  Karnofsky &gt;= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1 (and non-age adjusted
             CI &lt;=5 if &gt;45 years)

          -  Adequate renal, hepatic, pulmonary, and cardiac function

          -  Ability to understand and the willingness to sign a written informed consent form

        Exclusion Criteria:

          -  Uncontrolled viral or bacterial infection at the time of study enrollment

          -  Active or recent (prior 6 month) invasive fungal infection unless cleared by
             Infectious Disease (ID) consultant

          -  History of human immunodeficiency virus (HIV) infection

          -  Pregnant or breastfeeding

          -  Prior allogeneic transplant

          -  Central nervous system (CNS) leukemic involvement not clearing with intrathecal
             chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Milano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

